A detailed history of Affinity Asset Advisors, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 100,000 shares of MDGL stock, worth $31.1 Million. This represents 3.67% of its overall portfolio holdings.

Number of Shares
100,000
Previous 110,000 9.09%
Holding current value
$31.1 Million
Previous $30.8 Million 31.14%
% of portfolio
3.67%
Previous 4.19%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$212.22 - $292.96 $2.12 Million - $2.93 Million
-10,000 Reduced 9.09%
100,000 $21.2 Million
Q2 2024

Aug 14, 2024

SELL
$193.33 - $291.99 $966,650 - $1.46 Million
-5,000 Reduced 4.35%
110,000 $30.8 Million
Q1 2024

May 14, 2024

BUY
$171.37 - $283.23 $2.57 Million - $4.25 Million
15,000 Added 15.0%
115,000 $30.7 Million
Q4 2023

Feb 13, 2024

BUY
$120.4 - $237.13 $1.81 Million - $3.56 Million
15,000 Added 17.65%
100,000 $23.1 Million
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $1.1 Million - $1.69 Million
-7,500 Reduced 8.11%
85,000 $12.4 Million
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $101,940 - $156,000
-500 Reduced 0.54%
92,500 $21.4 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $5.31 Million - $7.06 Million
23,000 Added 32.86%
93,000 $22.5 Million
Q4 2022

Feb 13, 2023

SELL
$58.39 - $296.54 $1.75 Million - $8.9 Million
-30,000 Reduced 30.0%
70,000 $20.3 Million
Q2 2022

Aug 12, 2022

BUY
$58.04 - $100.2 $1.45 Million - $2.51 Million
25,000 Added 33.33%
100,000 $7.16 Million
Q1 2022

May 13, 2022

BUY
$55.89 - $101.89 $558,900 - $1.02 Million
10,000 Added 15.38%
75,000 $7.36 Million
Q4 2021

Feb 11, 2022

BUY
$72.34 - $95.09 $4.7 Million - $6.18 Million
65,000 New
65,000 $5.51 Million
Q1 2021

May 14, 2021

SELL
$108.54 - $125.2 $542,700 - $626,000
-5,000 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$110.06 - $133.7 $550,300 - $668,500
5,000 New
5,000 $556,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.32B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.